Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by jordon3on Aug 31, 2018 12:33pm
94 Views
Post# 28549284

RE:RE:RE:RE:Screw the long term investor= consolidation=reverse split

RE:RE:RE:RE:Screw the long term investor= consolidation=reverse splitThanks for your thoughts Kmucha and thanks for expressing that yes we are intitled to our own opinions on this subject without posters getting their panties in a twist. 
 
PMN seems to have the goods and we will undoubtedly have a better idea of this after the Phase 1 clinicals are completed or maybe even sooner.
That alone would escalate the share price imo.

Talking hypothetically here...using current share price of 30 cents.

You say as an example (which I really appreciate) "ex) 100,000 shares/stock price $0.30 ($30,000 in PMN) ----10: 1 split  ----  now have 10,000 shares/stock price now at $3.00 ($30,000 in PMN) ---- where the stock price goes from here is up to the markets yes...but I still feel for the reasons above it will hold around $3.00 for the time being." 

I would still rather have the original 100,000 shares rise to $10/sh= $1,000,000
then a post consolidation of 10,000 shares rise to $50, $60 , $70. $80. $90 = $500,000 etc etc.

Bottom line the 10,000 shares would have to hit $100/sh to equal pre RS profit

What am I missing other than more exposure? From my perspective if you have the goods and can prove it, the world and entire investment community would soon find out. This investment community would want a piece of the action, no matter the exchange. I think all this exposure talk is over rated imo. This is a devastating disease, if a solution is found, just one tweet would send the investment community into search mode. 

Did Cyprus do a t 10-1 RS?   If so maybe that is anthony g's favorite number?
 


Bullboard Posts